Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.

Date publication

juillet 2026

Journal

Journal of hematology & oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr FEUGIER Pierre , Pr ROSSI Cédric , Dr MARCAIS Ambroise

Tous les auteurs :
Cartron G, Chaillol I, Houot R, Al Tabaa Y, Le Bras F, Ysebaert L, Choquet S, Jardin F, Bay JO, Gros FX, Morschhauser F, Rossi C, Gastinne T, Thieblemont C, Joris M, Ricard L, Regny C, La Rochelle LD, Feugier P, Marcais A, Ould-Ammar R, Tarte K, Laurent C, Sesques P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42393723

Résumé

Failure after anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in diffuse large B-cell lymphoma (DLBCL) is associated with poor survival and there is no established standard of care. We previously reported the phase 2 LYSA BiCAR trial of short-ramp-up glofitamab after CAR T-cell failure. Here, we present the final survival results and a pre-specified external comparative effectiveness analysis against a contemporary control arm constructed from academic data.

Mots clés

Bispecific antibodies, CAR T-cell therapy, Comparative effectiveness, Diffuse large B-cell lymphoma, External control, Glofitamab, LYSA, Real-world data

Référence

J Hematol Oncol. 2026 07 1;: